Although phyllodes tumor (PT) is an uncommon fibro epithelial tumor of the breast, due to its variation in nomenclature, presentation, and diagnosis, it has posed many problems for the surgeons around the world. Its clinical spectrum ranges from a benign, borderline to malignant with or without metastasis. Aim: This a prospective study, aims to evaluate clinical characteristics, Histopathological diagnosis, Treatment regimen, Recurrence and survival of the patients with late complications.Patients & Method: This study is done in V.S.S. Medical College, Burla, a rural hospital in India. Here we have enrolled 36 patients who are clinically, radiologically (USG &Mammography) and by FNAC, diagnosed as PT, under gone various type of surgical procedures and followed for recurrence and other late complications. Result: The mean age at diagnosis is 38.5 years, 25(69.4%) are benign, 4(9%) are borderline, and 7(19.5%) are malignant,. mean size of the tumor 7.12cm, right side tumors are 21 and left side are 14.patients are followed up for 6 to 36 month period with 7 (19.4%) recurrence, 9 loosed follow up and 2 died due to metastasis. Conclusion: For correct surgical planning, wider excision and to prevent local recurrence accurate preoperative pathological diagnosis is needed. It should be differentiated from malignant PT and other benign breast lesions and treat them accordingly
In the present article, we have established a result on generalized indexed absolute Norlund summability factor by generalizing results of Mishra and Srivastava on indexed absolute Cesaro summabilty factors and Padhy et.al. on the absolute indexed Norlund summability.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.